

NAME: Dr. Donia Hussein Abdelhameed Ahmed

Phone: +201069711755

Email: donia.hussein@med.aun.edu.eg

donia1hussein@gmail.com

Mailing Address: City Asyut, Assiut Governorate, Egypt

EDUCATION

- **Passed ESMO Examination held on 10th of September 2022. (ESMO accredited 2022).**
- **Medical Doctorate Degree student (MD and PhD) in Clinical Oncology, Faculty of Medicine, Assiut University, Egypt (ongoing, from October 2021 to be completed by 2025).**
- **MSc Degree in Clinical Oncology, Faculty of Medicine, Assiut University, Assiut Governorate, Egypt, 2021.**
- **Bachelor Of Medicine and General Surgery (MBBCh), Assiut University, Egypt (2016).**

CURRENT AND PREVIOUS APPOINTMENTS

- **Currently,** Clinical Research Fellow of Clinical Oncology, and Assistant Lecturer at clinical Oncology Department, Faculty of Medicine, Assiut University, Egypt (September 2021- till date).
- Demonstrator at Clinical Oncology Department, Assiut University, Egypt (September 2020 – August 2021).
- Clinical Oncology Resident at Assiut University Hospital, Egypt (March 2018- August 2020).
- House Officer at Assiut University Hospital, Egypt (March 2017-Feb 2018).

RESEARCH EXPERIENCE

- ***Master Thesis titled:*** “Prognostic Significance of Bioscore in Non-metastatic Breast Cancer” 2018-2020.
- ***Trial coordinator of ongoing (EMERALD-2 trial),*** in clinical oncology department site, Assiut University hospitals Assiut, Egypt, (9/2021). Study title: ‘Assess Efficacy and Safety of Durvalumab Alone or Combined with Bevacizumab in High Risk of Recurrence HCC patients After Curative Treatment’, Protocol ID: D910DC00001, Study Site Number: 8708, Study Status: ongoing.

- **MD degree Thesis titled:** ‘Prediction of Chemotherapy Toxicity and Survival in Elderly Cancer Patients by CARG Score’, Clinical Trials Number: NCT05432726, Status: Active, Recruiting, Start Date: 20. July.2022.

PUBLICATIONS

Papers:

- **Mohamed, R.F., Abdelhameed, D.H., and Mohamed, M.A.,** “Combination of Anatomical and Biological Factors to Predict Disease-Free Survival in Breast Cancer”, ASCO Journals, JCO Global Oncology Journal, Volume 9, 8. Mar.2023, DOI: <https://ascopubs.org/doi/full/10.1200/GO.22.00269>
- **Mohamed, R.F., Abdelhameed, D.H., and Abdeltawab, A.A.,** “EVALUATION OF KI-67 AS INDEPENDENT RISK FACTOR AND ITS ROLE IN THE INCIDENCE OF LOCAL RECURRENCE/DISTANT METASTASIS IN LUMINAL A AND LUMINAL B (HER2 NEGATIVE) BREAST CANCER: A RETROSPECTIVE ANALYSIS FROM A SINGLE CANCER CENTER”, World Cancer Research Journal, Volume 10, 27. Sep. 2023, DOI:10.32113/wcrj_20239_2675, <https://www.wcrj.net/article/2675>

Abstracts:

- **Abdelhameed, D.H., Mohamed, R.F., and Mohamed, M.A.,** ‘Biologic factors of breast cancer and DFS’, Annals of Oncology, Volume 32, Issue S6, 2021, (poster presentation on MAP Virtual Congress, October 2021), DOI: [https://www.annalsofoncology.org/article/S0923-7534\(21\)04310-6/pdf](https://www.annalsofoncology.org/article/S0923-7534(21)04310-6/pdf)
- **Kelany, M., Abdeltawab, A.A., Abdelhameed, D.H., Mohamed, M.N., and Atef, D.** ‘CLINICAL- EPIDEMIOLOGICAL AND TREATMENT FACTORS IMPACT ON SURVIVAL IN EGYPTIAN PATIENTS WITH HEAD AND NECK SARCOMA: A RETROSPECTIVE CASE-SERIES ANALYSIS’. (poster presentation on the 2022 CTOS Annual Meeting), November 16-19 at the Vancouver Convention Centre in Vancouver, BC, Canada. (Abstract ID: 2206550), DOI: <https://www.eventscribe.net/2022/CTOS/fsPopup.asp?PosterID=526088&mode=posterinfo>
- **Mohamed, R.F., Abdelhameed, D.H., and Abdeltawab, A.A.,** “INCIDENCE OF LOCAL RECURRENCE/DISTANT METASTASIS IN LUMINAL A AND LUMINAL B (HER2- NEGATIVE) BREAST CANCER IN ACCORDANCE TO KI-67 INDEX”, Tumori Journal, 15th BGICC Abstract Book 2023, Volume 109, Issue 1_suppl, (poster presentation on BGICC conference, Egypt, January. 2023) DOI: <https://doi.org/10.1177/03008916231152348>

PRESENTATIONS, CONFERENCE ABSTRACTS AND INVITED LECTURES

- **‘Recurrent Pancreatic Cancer Case Discussion’** Presentation in Pancreology Meeting, Cairo Journal Club, Egypt, (5-6 September 2024).
- **“Prognostic Significance of Bioscore in Non-metastatic Breast Cancer”** Presentation in the Annual Scientific Conference of Alexandria Clinical Oncology Department, Egypt, (November.2023).
- **“Oligometastatic Bladder Cancer” Case Presentation**, ESO Master Class in Clinical Oncology Autumn Edition, Varese, Italy, (October.2023).
- **‘Intestinal obstruction management’ Case presentation** in the Global Cancer Care Egypt Palliative Care ECHO Program, virtual (August.2023).
- **Multiple local teaching lectures in our institute for academic teaching undergraduates and oncology residents in Faculty of Medicine, Assiut University, Egypt.**

GRANTS AND AWARDS

-**Title of Award:** participation in the Oncolympics, a competition held between oncology institutions in Egypt from June to October 2021. The event, sponsored by AstraZeneca, the institution's team emerged as the first champions and won a travel grant to attend the ESMO Breast Congress in May 2023.

-**ASCO Mentorship 2024.**

PROFESSIONAL TRAINING/ RELEVANT COURSES

- **ESO-Refresher Course on Prostate Cancer on 24-26 May 2024, Ljubljana, Slovenia.**
- **ESO-Master Class in Clinical Oncology-Autumn Edition on (6-10. October. 2023), Varese, Milan, Italy.**
- **ESMO Congress 2023 (virtual attendance).**
- **ESMO Breast Cancer Congress 2023, physical attendance on Berlin, May.2023.**
- **European Lung Cancer Congress 2023.**
- **ESMO Virtual Advanced Course on ‘NTRK Gene Fusion: A New Target in Precision Treatment of Cancer’ (5-6 December 2022).**
- **Molecular Analysis for Precision Oncology conference, October 2022.**
- **ESMO Breast Cancer 2022 (virtual attendance). ESMO Breast Cancer Virtual Congress 2020.**
- **ESMO Breast Cancer Virtual Congress 2021. ESMO Congress 2021.**

LEADERSHIP & MANAGEMENT EXPERIENCE

-Member of the scientific organizing committee of the Annual Clinical Oncology Conference, Clinical Oncology Department, Faculty of Medicine, Assiut University, Egypt and the Annual Conference of the Faculty of Medicine, Assiut University, Egypt (2021- till date). **LANGUAGES: English:** Excellent language. **Arabic:** Native Language.